Oncology
China’s Biliary-Cancer Bet Has a Global Access Problem
A pivotal Chinese Phase II study of fanregratinib has reported a meaningful response signal in FGFR2-altered intrahepatic cholangiocarcinoma. The science is moving. The global testing and access pathway is still lagging behind.
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
Regulators Start Writing the Rules for AI-Driven Medicines
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.